Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

Journal of Clinical Oncology

Volumn 18, Issue 3, 2000, Pages 547-561

  Kantarjian, Hagop M ^a   O'Brien, Susan ^a   Smith, Terry L ^a   Cortes, Jorge ^a   Giles, Francis J ^a   Beran, Miloslav ^a   Pierce, Sherry ^a   Huh, Yang ^a   Andreeff, Michael ^a   Koller, Charles ^a   Ha, Chul S ^a   Keating, Michael J ^a   Murphy, Sharon ^a   Freireich, Emil J ^a  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUCONAZOLE; FOLINATE CALCIUM; GRANULOCYTE COLONY STIMULATING FACTOR; LEVOFLOXACIN; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; VALACICLOVIR; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; B CELL LEUKEMIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; DOSE RESPONSE; FEMALE; HUMAN; LEUKOCYTOSIS; LIVER DYSFUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM MASS; MUCOSA INFLAMMATION; NEUTROPENIA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SURVIVAL RATE; T CELL LEUKEMIA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0033964380     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.3.547     Document Type: Article

References (82)

1. Pui C-H, Evans WE: Acute lymphoblastic leukemia. N Engl J Med 339:605-615, 1998
2. Pinkel D: Curing children of leukemia. Cancer 60:1683-1691, 1987
3. Kantarjian HM, Walters RS, Keating MJ, et al: Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol 8:994-1004, 1990
4. Preti A, Kantarjian HM: Management of adult acute lymphocytic leukemia: Present issues and key challenges. J Clin Oncol 12:1312-1322, 1994
5. Kantarjian HM: Adult acute lymphocytic leukemia: Critical review of current knowledge. Am J Med 97:176-184, 1994
6. Hoelzer D, Thiel E, Loffler H, et al: Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 71:123-131, 1988
7. Gaynor J, Chapman D, Little C, et al: A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia. J Clin Oncol 6:1014-1030, 1988
8. Hoelzer DR: Therapy of the newly-diagnosed adult with acute lymphoblastic leukemia. Hematol Oncol Clin North Am 7:139-160, 1993
9. Hussein KK, Dahlberg S, Head D, et al: Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood 73:57-63, 1989
10. Larson RA, Dodge RK, Burns CP, et al: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811. Blood 85:2025-2037, 1995
11. Amadori S, Montuoro A, Meloni G, et al: Combination chemotherapy for acute lymphocytic leukemia in adults: Results of a retrospective study in 82 patients. Am J Hematol 8:175-183, 1980
12. Linker CA, Levitt LJ, O'Donnell M, et al: Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: A follow-up report. Blood 78:2814-2822, 1991
13. Radford JE, Burns CP, Jones MP, et al: Adult acute lymphoblastic leukemia: Results of the Iowa HOP-L protocol. J Clin Oncol 7:58-66, 1989
14. Preti HA, O'Brien S, Giralt S, et al: Philadelphia-chromosome-positive adult acute lymphocytic leukemia: Characteristics, treatment results, and prognosis in 41 patients. Am J Med 97:60-65, 1994
15. Kantarjian HM, Talpaz M, Dhingra E, et al: Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood 78:2411-2418, 1991
16. Westbrook CA, Hooberman AL, Spino C, et al: Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: A Cancer and Leukemia Group B study (8762). Blood 80:2983-2990, 1992
17. Barrett AJ, Horowitz MM, Ash RC, et al: Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 79:3067-3070, 1992
18. Murphy SB, Bowman WP, Abromowitch M, et al: Results of the treatment of advanced-stage Burkitt's lymphoma and B cell (Sig+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol 4:1732-1739, 1986
19. Bowman WP, Shuster JJ, Cook B, et al: Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: A Pediatric Oncology Group study. J Clin Oncol 14:1252-1261, 1996
20. Patte C, Philip T, Rodary C, et al: High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: Results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 9:123-132, 1991
21. 3 ALL) in adults: A report of 18 cases. Br J Haematol 71:371-376, 1989
22. Hoelzer D, Ludwig WD, Thiel E, et al: Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 87:495-508, 1996
23. McMaster ML, Greer JP, Greco A, et al: Effective treatment of small-noncleaved-cell lymphoma with high-intensity, brief duration chemotherapy. J Clin Oncol 9:941-946, 1991
24. Richards S, Burrett J, Hann I, et al: Improved survival with early intensification: Combined results from the Medical Research Council childhood ALL randomised trials, UKALL X and UKALL XI -Medical Research Council Working Party on Childhood Leukaemia. Leukemia 12:1031-1036, 1998
25. Clavell LA, Gelber RD, Cohen HJ, et al: Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 315:657-663, 1986
26. Pui C-H, Simone JV, Hancock ML, et al: Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: Long-term results of St Jude total therapy study X. Leukemia 6:150-157, 1992
27. Abromowitch M, Fairclough D: Contribution of mercaptopurine dose intensification to improved outcome in patients with lower-risk ALL. J Clin Oncol 8:1442-1443, 1990
28. Camitta B, Leventhal B, Lauer S, et al: Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: A Pediatric Oncology Group study. J Clin Oncol 10:1539-1544, 1989
29. Rivera GK, Raimondi SC, Hancock ML, et al: Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination. Lancet 337:61-66, 1991
30. Tubergen DG, Gilchrist GS, O'Brien RT, et al: Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: A Childrens Cancer Group phase III trial. J Clin Oncol 11:527-537, 1993.
31. Reiter A, Schrappe M, Ludwig W-D, et al: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122-3133, 1994
32. Hoelzer D: Acute lymphoblastic leukemia: Progress in children, less in adults. N Engl J Med 329:1343-1344, 1993
33. Bassan R, Lerede T, Barbui T: Institutional performance and dose intensity as prognostic factors in adult ALL. Leukemia 9:933-936, 1995
34. Todeschini G, Meneghini V, Pizzolo G, et al: Relationship between daunorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemia. Leukemia 8:376-381, 1994
35. Todeschini G, Tecchio C. Meneghini V, et al: Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin. Leukemia 12:144-149, 1998
36. Chiu EKW, Chan LC, Liang R, et al: Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia: A possible dose effect. Leukemia 8:1469-1473, 1994
37. Scherrer R, Geissler K, Kyrle PA, et al: Granulocyte colony-stimulating factor (G-CSF) as an adjunct to induction chemotherapy of adult acute lymphoblastic leukemia (ALL). Ann Hematol 66:283-289, 1993
38. Kantarjian HM, Estey E, O'Brien S, et al: Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission. Cancer 72:2950-2955, 1993
39. Kantarjian HM, Estey EH, O'Brien S, et al: Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia. Blood 79:876-881, 1992
40. Ottmann OG, Hoelzer D, Gracien E, et al: Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: A randomized phase III trial. Blood 86:444-450, 1995
41. Geissler K, Koller E, Hubmann E, et al: Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia: A randomized phase-III study. Blood 90:590-596, 1997
42. Ottmann OG, Hoelzer D: Do G-CSF and GM-CSF contribute to the management of acute lymphoblastic leukemia? Leukemia 10:1111-1116, 1996
43. Welte K, Reiter A, Mempel K, et al: A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Blood 87:3143-3150, 1996
44. Larson RA, Dodge RK, Linker CA, et al: A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB Study 9111. Blood 92:1556-1564, 1998
45. Campana D, Coustan-Smith E, Manabe A, et al: Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein. Blood 81:1025-1031, 1993
46. Campos L, Sabido O, Sebban C, et al: Expression of BCL-2 proto-oncogene in adult acute lymphoblastic leukemia. Leukemia 10:434-438, 1996
47. Coustan-Smith E, Kitanaka A, Pui C-H, et al: Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood 87:1140-1146, 1996
48. Gala JL, Vermylen C, Cornu G, et al: High expression of bcl-2 is the rule in acute lymphoblastic leukemia, except in Burkitt subtype at presentation, and is not correlated with prognosis. Ann Hematol 69:17-24, 1994
49. Bennett JM, Catovsky D, Daniel MT, et al: The morphological classification of acute lymphoblastic leukaemia: Concordance among observers and clinical correlations. Br J Haematol 47:553-561, 1981
50. Wiersman SR, Ortega J, Sobel E, et al: Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. N Engl J Med 324:800-808, 1991
51. Mitelman F (ed): International System for Human Cytogenetics Nomenclature (ISCN 1995). Basel, Switzerland, Karger, 1995
52. Preti A, Kantarjian HM, Estey E, et al: Characteristics and outcome of patients with acute lymphocytic leukemia and myeloper-oxidase-positive blasts by electron microscopy. Hematol Pathol 8:155-167, 1994
53. Preti HA, Huh YO, O'Brien SM, et al: Myeloid markers in adult acute lymphocytic leukemia: Correlations with patient and disease characteristics and with prognosis. Cancer 76:1564-1570, 1995
54. Ito BC, Evans WE, McNinch L, et al: Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol 14:2370-2376, 1996
55. Kantarjian HM, Walters RS, Smith TL, et al: Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood 72:1784-1789, 1988
56. Cortes J, O'Brien S, Pierce S, et al: The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 86:2091-2097, 1995
57. National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
58. Kaplan FL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 52:457-481, 1958
59. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
60. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
61. Grambsch PM, Therneau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515-526, 1994
62. Therneau TM, Grambsch PM, Fleming TR: Martingale-based residuals for survival models. Biometrika 77:147-160, 1990
63. Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343-346, 1996
64. Uckun FM, Sather HN, Gaynon PS, et al: Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood 90:28-35, 1997
65. Putti MC Rondelli R, Cocito M-G, et al: Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 studies. Blood 9:795-801, 1998
66. Pui C-H Mahmoud HH, Rivera GK, et al: Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood 92:411-415, 1998
67. Asselin BL, Whitin JC, Coppola DJ, et al: Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 11:1780-1786, 1993
68. Keating MJ, Holmes R, Lerner S, et al: L-Asparaginase and PEG asparaginase: Past, present, and future. Leuk Lymphoma 10:153-157, 1993 (suppl)
69. Frankel SR, Kurtzberg J, Deoleivera D, et al: Toxicity and pharmacokinetics of PEG-asparaginase in newly-diagnosed adult acute lymphoblastic leukemia: CALGB 9511. Blood 88:669a, 1996 (suppl 1, abstr)
70. Kurtzberg J, Keating M, Moore JO, et al: 2-Amino-9-B-arabinosyl-6-methoxy-9H-guanine (GW506U;Compound 506U) is highly active in patients with T-cell malignancies: Results of a phase I trial in pediatric and adult patients with refractory hematological malignancies. Blood 88:699a, 1996 (abstr)
71. Beran M, Cao X, Estrov Z, et al: Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res 4:1661-1672, 1998
72. Druker BJ, Sawyers CL, Talpaz M, et al: Phase I trial of a specific ABL tyrosine kinase inhibitor, CGP 57148, in interferon refractory chronic myelogenous leukemia patients. Proc Am Soc Clin Oncol 18:7a, 1999 (abstr 24)
73. Thomas D, Kantarjian H, O'Brien S, et al: Outcome with the Hyper-CVAD regimen in lymphoblastic lymphoma (LL). Proc Am Soc Clin Oncol 18:11a, 1999 (abstr 38)
74. Evans WE, Relling MV, Rodman JH, et al: Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499-505, 1998
75. Mahoney DH, Shuster J, Nitschke R, et al: Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: A Pediatric Oncology Group phase III trial. J Clin Oncol 16:246-254, 1998
76. Schmiegelow K, Schroder H, Gustafsson G, et al: Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. J Clin Oncol 13:345-351, 1995
77. Koizumi S, Fujimoto T, Takeda T, et al: Comparison of intermittent or continuous methotrexate plus 6-mercaptopurine in regimens for standard-risk acute lymphoblastic leukemia in childhood (JCCLSG-S811). Cancer 61:1292-1300, 1988
78. Lockhart S, Plunkett W, Jeha S, et al: High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia. J Clin Oncol 12:587-595, 1994
79. Pinkel D: Intravenous mercaptopurine: Life begins at 40. J Clin Oncol 11:1826-1831, 1993
80. Thomas D, Cortes J, O'Brien S, et al: Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 17: 2461-2470, 1990
81. Dimopoulos MA, Weber D, Kantarjian H, et al: HyperCVAD for VAD-resistant multiple myeloma. Am J Hematol 52:77-81, 1996
82. Khouri IF, Romaguera J, Kantarjian H, et al: Hyper-CVAD and high dose methotrexate/cytarabine followed by stem cell transplantation: An active regimen for aggressive mantle cell lymphoma. J Clin Oncol 16:3803-3809, 1998